[1]Evans M, et al. A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives[J]. Adv Ther. 2022 Jan;39(1):33-43.
[2]Sebastian SA, et al. Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review[J]. Curr Probl Cardiol. 2024 Feb;49(2):102344.
[3]Borrelli S, et al. Sodium Intake and Chronic Kidney Disease[J]. Int J Mol Sci. 2020 Jul 3;21(13):4744.
[4]Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease[J]. Kidney Int. 2024;105(4S):S117-S314.
[5]中国医药教育协会临床肾脏病专委会,慢性肾脏病多学科临床管理路径专家共识委员会. 慢性肾脏病多学科临床管理路径专家共识[J]. 中华内科杂志,2024,63(12):1216-1227.
[6]中华预防医学会肾脏病预防与控制专业委员会. 中国慢性肾脏病早期评价与管理指南[J]. 中华内科杂志,2023,62(8):902-930.
[7]Wang L, et al. Prevalence of Chronic Kidney Disease in China: Results From the Sixth China Chronic Disease and Risk Factor Surveillance[J]. JAMA Intern Med. 2023 Apr 1;183(4):298-310.
[8]Nie S, et al. Characteristics of patients with undiagnosed stage 3 chronic kidney disease: results from an observational study (REVEAL-CKD) in China[J]. Lancet Reg Health West Pac. 2025 Jan 4;54:101275.
[9]Marassi M, et al. The cardio-renal-metabolic connection[J]. Cardiovasc Diabetol. 2023 Jul 31;22(1):195.
[10]Yang C, et al. CKD in China: Evolving Spectrum and Public Health Implications[J]. Am J Kidney Dis. 2020 Aug;76(2):258-264.
[11]Ji L, et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study[J]. Clin Ther. 2014 Jan;36(1):84-100.
[12]Gao YM, et al. Cardiorenal protection of SGLT2 inhibitors-Perspectives from metabolic reprogramming[J]. EBioMedicine. 2022 Sep;83:104215.
[13]Feijóo-Bandín S, et al. Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models[J]. Int J Mol Sci. 2022 May 18;23(10):5634.
[14]Yang L, et al. Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis[J]. Front Endocrinol (Lausanne). 2022 Dec 15;13:992937.
[15]Ke Q, et al. SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney[J]. FASEB J. 2022 Jan;36(1):e22078.
[16]Terasaki M, et al. Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice[J]. PLoS One. 2015 Nov 25;10(11):e0143396.
[17]Brata R, et al. Hemodynamic Effects of SGLT2 Inhibitors in Patients with and Without Diabetes Mellitus-A Narrative Review[J]. Healthcare (Basel). 2024 Dec 6;12(23):2464.
[18]McCullough PA, et al. Cardiorenal Nexus: A Review With Focus on Combined Chronic Heart and Kidney Failure, and Insights From Recent Clinical Trials[J]. J Am Heart Assoc. 2022 Jun 7;11(11):e024139.
[19]Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease[J]. N Engl J Med. 2020 Oct 8;383(15):1436-1446.
[20]The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease[J]. N Engl J Med. 2023 Jan 12;388(2):117-127.
[21]"三高"共管规范化诊疗中国专家共识（2023版）专家组. "三高"共管规范化诊疗中国专家共识（2023版）[J]. 中华心血管病杂志（网络版）,2023,06(1):1-11.
[22]American Diabetes Association Professional Practice Committee. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024[J]. Diabetes Care. 2024;47(Suppl 1):S158-S178.
